ALEC - NASDAQ
Alector, Inc.
$1.95
-6.1%Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotAlector, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Alector, Inc. Income Statement
ALEC • NASDAQ
| Alector, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||
21M | 100.6M | 97.1M | 133.6M | 207.1M | 21.1M | 21.2M | 27.7M | 3.7M | 416K | |
GROSS PROFIT | ||||||||||
(9.7M) | (0.0) | (8.8M) | (0.0) | (189.4M) | (156.9M) | (100.5M) | (73M) | (29.9M) | (13.7M) | |
11.4M | 100.6M | 88.2M | 133.6M | 17.7M | -135.8M | -79.3M | -45.4M | -26.2M | -13.3M | |
OPERATING INCOME | ||||||||||
(157.2M) | (245.6M) | (240M) | (271.5M) | (55M) | (59.4M) | (135.6M) | (85M) | (36.4M) | (15.5M) | |
(54M) | (59.6M) | (56.7M) | (61M) | (55M) | (59.4M) | (35.1M) | (11.9M) | (6.5M) | (1.9M) | |
(123.1M) | (185.9M) | (192.1M) | (210.4M) | (189.4M) | (156.9M) | (100.5M) | (73M) | (29.9M) | (13.7M) | |
-145.8M | -145M | -151.7M | -137.8M | -37.4M | -195.2M | -114.4M | -57.3M | -32.7M | -15.1M | |
PRE-TAX INCOME | ||||||||||
-19.9M | (0.0) | -8.8M | (0.0) | -189.4M | -156.9M | (0.0) | (5M) | (199K) | (22K) | |
3M | 26.1M | 26.6M | 7.8M | 1M | 4.9M | 9M | 5M | 199K | 22K | |
-142.8M | -118.9M | -125.2M | -130.1M | -36.3M | -190.2M | -105.4M | -52.2M | -32.5M | -15.1M | |
NET INCOME | ||||||||||
(168K) | (128K) | (5.2M) | (3.3M) | (0.0) | (0.0) | -5.6M | (0.0) | (0.0) | (0.0) | |
-142.9M | -119M | -130.4M | -133.3M | -36.3M | -190.2M | -105.4M | -52.2M | -32.5M | -15.1M |
SEC Filings
ALEC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | April 21, 2026 | 2026 | |
S-3 S-3 N/A | March 12, 2026 | March 12, 2026 | ||
10-K 10-K 2025 FY FY | February 25, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 25, 2026 | February 25, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 12, 2025 | December 10, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 |
Related Guides
Continue your ALEC research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.